John Fairbanks, diagnosed with AL Amyloidosis, underwent CAR-T cell therapy as part of a clinical trial, achieving complete remission and improved organ function. Fairbanks became part of a clinical trial testing CAR-T cell therapy as a treatment for amyloidosis. Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. But when Fairbanks faced a disease that threatened his life, it was another kind of "car" that would make the difference. "Well I started this battle, and I call it a battle, in 2022," Fairbanks said. Fairbanks was diagnosed with AL Amyloidosis, a rare and potentially deadly disease in which abnormal proteins accumulate in the body's organs, damaging vital systems such as the heart, liver and kidneys. "This therapy called NX 201 at the moment and is a form of a CAR-T cell therapy.

Original title: “'Unreal': North Texas man in remission after experimental treatment”

Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. To stream WFAA on your phone, you need the WFAA app. ... MANSFIELD, Texas — John Fairbanks knows a thing or two about cars. His pride and joy is a meticulously restored bright red 1967 Ford Mustang Fastback, a classic he rebuilt from the frame up. But when Fairbanks faced a disease that threatened his life, it was another kind of "car" that would make the difference. Fairbanks became part of a clinical trial testing CAR-T cell therapy as a treatment for amyloidosis. Fairbanks was diagnosed with AL Amyloidosis, a rare and potentially deadly disease in which abnormal proteins accumulate in the body's organs, damaging vital systems such as the heart, liver and kidneys. "This therapy called NX 201 at the moment and is a form of a CAR-T cell therapy.

Original title: “'Unreal': North Texas man in remission after experimental treatment | wfaa.com”

Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. To stream KVUE on your phone, you need the KVUE app. ... MANSFIELD, Texas — John Fairbanks knows a thing or two about cars. His pride and joy is a meticulously restored bright red 1967 Ford Mustang Fastback, a classic he rebuilt from the frame up. But when Fairbanks faced a disease that threatened his life, it was another kind of "car" that would make the difference. Fairbanks became part of a clinical trial testing CAR-T cell therapy as a treatment for amyloidosis. Fairbanks was diagnosed with AL Amyloidosis, a rare and potentially deadly disease in which abnormal proteins accumulate in the body's organs, damaging vital systems such as the heart, liver and kidneys. "This therapy called NXC-201 at the moment and is a form of a CAR-T cell therapy.

Original title: “'Unreal': North Texas man in remission after experimental treatment | kvue.com”

The treatment improved his condition but did not eliminate the disease. He eventually learned about an investigational CAR-T cell therapy. CAR-T therapy involves collecting a patient's immune cells and modifying them so they can recognize and attack targeted cells. Lomonaco was able to enroll in a clinical trial ... The treatment improved his condition but did not eliminate the disease. He eventually learned about an investigational CAR-T cell therapy. CAR-T therapy involves collecting a patient's immune cells and modifying them so they can recognize and attack targeted cells. Lomonaco was able to enroll in a clinical trial and received the treatment at The James Cancer Hospital at The Ohio State University. He was diagnosed with AL amyloidosis, a rare disease that causes abnormal proteins to build up in the body's organs The treatment Lomonaco received is not yet widely available. He said the clinical trial closed shortly after he underwent the procedure, leaving other people with the disease without the same option. After about a year of tests and visits to several doctors, Michael Lomonaco was diagnosed with AL amyloidosis, a rare disease that causes abnormal proteins to build up in the body's organs. In Lomonaco's case, the disease was affecting his heart. (provided) ... LOVELAND, Ohio (WKRC) - A Loveland man who once struggled to walk from his car to his desk without stopping to catch his breath is now back to exercising after an experimental treatment for a rare disease.

Original title: “Loveland man credits experimental treatment with putting rare disease in remission”

raccoon eye as the sole presenting sign of al amyloidosis associated with a low burden clonal plasma cell neoplasm

Original title: “Raccoon eye as the sole presenting sign of AL amyloidosis associated with a low-burden clonal plasma cell neoplasm.”

cardiac tamponade from lymphocytic constrictive pericarditis in primary al amyloidosis without myocardial involvement

Original title: “Cardiac Tamponade From Lymphocytic Constrictive Pericarditis in Primary AL Amyloidosis Without Myocardial Involvement.”

efficacy and safety of bcma targeted therapies in relapsed or refractory al amyloidosis a descriptive pooled analysis

Original title: “Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis.”

We’re studying BCMA-directed ... unprecedented, but regulators are mandating randomized clinical trials to prove the benefit of these transformative therapies. I find it a big issue when you have a rare disease to have to do a large, randomized trial, which can only be ... We’re studying BCMA-directed therapies in this space, and there are excellent response rates and safety profiles that are unprecedented, but regulators are mandating randomized clinical trials to prove the benefit of these transformative therapies. I find it a big issue when you have a rare disease to have to do a large, randomized trial, which can only be ethically done in the upfront setting, because there’s nothing approved in the relapsed setting. Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder. ... Amyloid light-chain (AL) amyloidosis is a disease with a more challenging prognosis than other plasma cell disorders like multiple myeloma due to cardiac and other organ involvement and lack of survival benefit from many established myeloma therapies. However, using B-cell maturation antigen (BCMA) as a target has shown promise for chimeric antigen receptor (CAR) T-cell therapy, opening up a new single-infusion treatment approach in this rare disease setting. In the phase 1/2 NEXICART-2 trial (NCT06097832), the investigational CAR T-cell therapy NXC-201 What was really impressive and different was what we saw was the patients who were sickest coming into the trial, who had high light chains or obvious organ progression due to their relapsing disease, experienced significant clinical benefit very rapidly—as soon as the light chains were controlled. I can’t say I’ve witnessed that with any other therapy that I’ve given.

Original title: “Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways”

attenuated prognostic discrimination among mayo stages i iiia and improved survival in stage iiib in the daratumumab era a real world study of newly diagnosed al amyloidosis

Original title: “Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.”

negative 99mtc tc dpd scintigraphy presence of monoclonal protein and biopsy suggestive of al amyloidosis in a patient with homozygous p ala101val transthyretin gene variant

Original title: “Negative [99mTc]Tc -DPD Scintigraphy, Presence of Monoclonal Protein and Biopsy Suggestive of AL Amyloidosis in a Patient With Homozygous p.Ala101Val Transthyretin Gene Variant.”

an australian amyloidosis network analysis of australian patients with immunoglobulin light chain amyloidosis treated with bortezomib based chemotherapy

Original title: “An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy.”